Lymphoma Forces Young T Cells to Age Decades in Just Days
B cell lymphoma rapidly drives young T cells into a molecular and epigenetic aged state, while truly old T cells prove strangely resistant.
Summary
Researchers at Moffitt Cancer Center discovered that B cell lymphoma alone — without any treatment — is sufficient to trigger accelerated aging in young T cells and multiple tissues. Using mouse lymphoma models and human DLBCL patient samples, they showed that lymphoma rapidly induces in young T cells the same transcriptional, epigenetic, and phenotypic hallmarks seen in aged T cells, including senescence markers, inflammation, disrupted iron homeostasis, and defective protein quality control. Paradoxically, aged T cells were largely resistant to these lymphoma-driven changes. Some lymphoma-induced aging phenotypes reversed after tumor clearance, while others persisted, suggesting that cancer-driven aging is partially but not fully reversible.
Detailed Summary
Cancer survivors frequently experience accelerated aging, but this has historically been attributed to harsh therapies like chemotherapy and radiation rather than to the cancer itself. This landmark study asks a provocative question: can lymphoma alone — independent of treatment — drive systemic aging?
Using young (6–12 weeks) and aged (78+ weeks) mice transplanted with Eμ-Myc B cell lymphomas, alongside transcriptomic, epigenomic, and flow cytometric analyses of human DLBCL patient T cells, the researchers systematically mapped how lymphoma reshapes immune cell biology across age groups. Single-cell RNA sequencing and ATAC-seq were central tools, enabling resolution of chromatin accessibility and gene expression changes at the individual cell level.
The core finding is striking: lymphoma drives young T cells to rapidly acquire the transcriptional, epigenetic, and phenotypic signatures of aged T cells. These include upregulation of senescence markers (KLRG1, p16INK4a/CDKN2A), pro-inflammatory transcription factors (TBET, TOX, FOXP3), exhaustion markers (PD-1, CD39), and disrupted iron homeostasis. Chromatin accessibility analyses revealed that open chromatin regions controlling iron metabolism are induced by both aging and lymphoma exposure. Strikingly, lymphoma-experienced and aged T cells both showed increased intracellular iron pools and acquired resistance to ferroptosis — iron-dependent programmed cell death — a potentially dangerous convergence. Both aged and lymphoma-experienced T cells also displayed defects in proteostasis, including reductions in endoplasmic reticulum integrity and protein quality control pathways.
In a counterintuitive twist, aged T cells were largely resistant to the phenotypic changes that lymphoma imposed on young T cells. Adoptive transfer experiments confirmed this resistance is cell-intrinsic rather than a product of the aged microenvironment. This suggests that aged T cells, already in a stabilized senescent-like state, cannot be further destabilized by lymphoma-derived signals in the same way.
Lymphoma-accelerated aging was not confined to T cells. Tissues including liver and other organs from young lymphoma-bearing mice showed elevated expression of Cdkn2a (p16INK4a) and Tnfa, canonical markers of cellular senescence and inflammaging. This systemic aging effect reinforces the idea that cancer creates a body-wide aging environment. Importantly, when lymphoma was selectively cleared in young mice, some aging-associated changes reversed while others persisted, indicating a window — but a limited one — for therapeutic intervention to mitigate cancer-driven aging comorbidities.
Key Findings
- Lymphoma alone drives young T cells to acquire transcriptional and epigenetic signatures of aged T cells within 12 days.
- Both aged and lymphoma-experienced T cells show elevated iron pools and resistance to ferroptosis via shared chromatin remodeling.
- Aged T cells are intrinsically resistant to lymphoma-induced phenotypic changes, even in a young host microenvironment.
- Lymphoma accelerates systemic tissue aging, elevating p16INK4a and TNF-alpha expression in non-immune tissues of young mice.
- Some lymphoma-induced aging phenotypes reverse after tumor clearance; others are fixed, suggesting partial reversibility.
Methodology
The study used young (6–12 week) and aged (78+ week) mice transplanted with Eμ-Myc B cell lymphomas, plus Myd88L252P/BCL2-driven DLBCL mouse models. Splenic T cells were analyzed by flow cytometry, single-cell RNA sequencing, and ATAC-seq. Human validation used T cells from young and aged healthy donors and relapsed/refractory DLBCL patients.
Study Limitations
Most mechanistic data derive from mouse transplant models that may not fully capture spontaneous human lymphoma biology. Human patient samples were from relapsed/refractory disease, making it difficult to disentangle cancer-intrinsic effects from prior treatment history. The specific molecular mechanisms linking lymphoma to iron homeostasis dysregulation in T cells require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.